LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced that its representatives plan to attend MEDICA 2026 in Dusseldorf, Germany. The event, one of the world’s largest international healthcare and medical technology trade fairs, will provide the Company with opportunities to evaluate emerging technologies, engage with industry stakeholders, and advance its long-term digital healthcare infrastructure strategy across Latin America.
Management stated that attendance at MEDICA is intended to support the Company’s ongoing evaluation of healthcare technologies, strategic industry relationships, vendor solutions, digital infrastructure initiatives, and broader commercialization opportunities. The Company plans to engage with healthcare technology providers, telehealth vendors, pharmaceutical infrastructure participants, medical software developers, AI-focused healthcare companies, and other industry stakeholders from Europe, Latin America, and additional international markets.
“Healthcare systems around the world are rapidly moving toward technology-driven and AI-enabled infrastructure models,” said Dr. Kevin Rodan Levy, CEO of LataMed AI Corp. “Our attendance at MEDICA reflects our commitment to engaging with industry participants, evaluating emerging technologies, and continuing to build a scalable healthcare platform designed to support long-term digital healthcare modernization initiatives throughout Latin America.”
The Company remains in the development and commercialization stage with respect to certain aspects of its healthcare technology platform and business operations. It cautioned that attendance at industry conferences does not guarantee strategic relationships, commercial agreements, financing arrangements, technology integrations, revenue generation, or future operational success.
LataMed AI Corp. continues to advance telehealth deployment initiatives, healthcare analytics integration, operational scalability planning, strategic relationship development, and broader commercialization efforts. The Company is focused on building a technology-enabled healthcare ecosystem to support remote patient engagement, provider coordination, healthcare analytics, emergency response integration, pharmaceutical logistics, and broader digital healthcare delivery initiatives in emerging markets.
For more information, visit https://latamed.ai or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
